Vanguard Group Inc. Sells 96,114 Shares of Artivion, Inc. (NYSE:AORT)

Vanguard Group Inc. decreased its holdings in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 3.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,646,643 shares of the company's stock after selling 96,114 shares during the period. Vanguard Group Inc. owned approximately 6.46% of Artivion worth $40,123,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Money Concepts Capital Corp purchased a new position in shares of Artivion during the fourth quarter valued at approximately $28,000. Tower Research Capital LLC TRC lifted its stake in Artivion by 89.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,677 shares of the company's stock valued at $29,000 after acquiring an additional 791 shares in the last quarter. Captrust Financial Advisors bought a new position in Artivion during the 2nd quarter valued at $39,000. State of Wyoming boosted its holdings in Artivion by 207.1% during the 4th quarter. State of Wyoming now owns 3,495 shares of the company's stock worth $42,000 after acquiring an additional 2,357 shares during the last quarter. Finally, Advisor Group Holdings Inc. grew its stake in shares of Artivion by 54.0% in the 4th quarter. Advisor Group Holdings Inc. now owns 3,859 shares of the company's stock worth $47,000 after acquiring an additional 1,353 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a "buy" rating and set a $25.00 price target on shares of Artivion in a research report on Monday. Stifel Nicolaus lifted their target price on shares of Artivion from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, February 16th.

Insider Buying and Selling

In other news, VP Rochelle L. Maney sold 2,315 shares of the company's stock in a transaction on Monday, February 26th. The stock was sold at an average price of $20.27, for a total transaction of $46,925.05. Following the transaction, the vice president now owns 39,197 shares of the company's stock, valued at approximately $794,523.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Marshall S. Stanton sold 2,183 shares of Artivion stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total value of $44,511.37. Following the completion of the transaction, the senior vice president now directly owns 83,296 shares in the company, valued at approximately $1,698,405.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Rochelle L. Maney sold 2,315 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $20.27, for a total transaction of $46,925.05. Following the sale, the vice president now directly owns 39,197 shares in the company, valued at approximately $794,523.19. The disclosure for this sale can be found here. In the last quarter, insiders have sold 149,952 shares of company stock valued at $2,891,627. 6.60% of the stock is owned by company insiders.

Artivion Stock Performance

NYSE:AORT traded down $0.16 during trading on Wednesday, reaching $21.48. The company's stock had a trading volume of 159,843 shares, compared to its average volume of 230,173. Artivion, Inc. has a 12 month low of $12.16 and a 12 month high of $21.90. The firm has a market cap of $884.98 million, a price-to-earnings ratio of -28.63 and a beta of 1.67. The firm has a 50 day moving average of $19.42 and a 200-day moving average of $17.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.43 and a current ratio of 4.85.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.24. The business had revenue of $93.67 million during the quarter, compared to the consensus estimate of $89.75 million. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. Research analysts expect that Artivion, Inc. will post 0.26 EPS for the current fiscal year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.